Q2 FY2026 EarningsQ2 FY26 results beat consensus on earnings but missed on operating loss, with a GAAP EPS of -$1.97 vs. -$2.10 expected. The company reported $0 revenue, in-line with expectations for its clinical stage, while operating expenses of $302.8M exceeded the $315.7M EBIT loss forecast due to intensified Phase 3 clinical trial activities for VAX-31. Cash burn remains a focal point as net cash used in operating activities climbed to $513.1M for the first half of FY26.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Vaxcyte(PCVX) the EBIT is -302.78 M (-33.84%), Beat estimate;the EPS is -1.97 (-61.48%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITExceed expectations
-0.30B33.84%
-0.32B39.54%
+0.01B5.70%
EPSExceed expectations
-1.9761.48%
-2.102572.34%
+0.132510.86%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf